Skip to main content
All lobbying filings

Biomarin Pharmaceutical Inc.

Biomarin Pharmaceutical Inc. filed a Q2 report for Biomarin Pharmaceutical Inc. on July 21, 2025.

Lobbying for Biomarin Pharmaceutical Inc.

As filed: BIOMARIN PHARMACEUTICAL INC. for BIOMARIN PHARMACEUTICAL INC.

All filings by Biomarin Pharmaceutical Inc. · Everything Biomarin Pharmaceutical Inc. has reported

 Filing · LD-2 quarterly report Q2 report
Reporting period
2nd Quarter 2025
Apr 1 - June 30 · Posted Jul 21, 2025
Expenses
$270,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
California

Official filing document

 Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 4
Health Issues

HR 1262: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION S 932: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION GENERAL DISCUSSIONS REGARDING INFLATION REDUCTION ACT AND ORPHAN DRUGS GENERAL DISCUSSIONS REGARDING ORPHAN DRUG ACT GENERAL DISCUSSIONS REGARDING GENETIC SCREENING AND NEWBORN SCREENING

Medicare/Medicaid

H.R. 1: ONE BIG BEAUTIFUL BILL ACT; PROVISIONS RELATED TO TITLE VII, SUBTITLE B H.R. 946: ORPHAN Cures Act; ALL PROVISIONS H.R. 1509: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS OF THE BILL S. 752: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS OF THE BILL S. 1637: MEDICAID VBPS FOR PATIENTS (MVP) Act; ALL PROVISIONS S. 1862: ORPHAN Cures Act; ALL PROVISIONS GENERAL DISCUSSIONS REGARDING MEDICAID DRUG REBATE PROGRAM GENERAL DISCUSSIONS REGARDING FOREIGN DRUG REFERENCE PRICING

Tariff (miscellaneous tariff bills)

GENERAL DISCUSSIONS REGARDING TARIFFS ON PHARMACEUTICALS

Taxation/Internal Revenue Code

GENERAL DISCUSSIONS REGARDING ORPHAN DRUG TAX CREDIT

 Bills named in this filing 7

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem